2023 Total Revenue of ~$399.4M, a 21% Increase Year-Over-Year
Go here to read the rest:
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
COPENHAGEN, Denmark, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today introduced selected 2024 corporate milestones and Vision 2030, its strategic roadmap through 2030. Ascendis President and CEO Jan Mikkelsen will present the update tomorrow, January 8, at the 42nd Annual J.P. Morgan Healthcare Conference.
Read more from the original source:
Ascendis Pharma Introduces Vision 2030
ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024;Potential to be First Approved Treatment for GBS Patients in the U.S.
Here is the original post:
Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and...
Reported $1.2 billion in preliminary* full-year 2023 global net product sales
Visit link:
argenx Highlights 2024 Strategic Priorities
Expect 10% growth in RUCONEST® revenue, significantly exceeding prior guidance
Read more:
Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
Continued here:
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
January 8, 2024 – release at 7:30 am CETSophia Antipolis, France
Read the original post:
Nicox : Half-year liquidity contract statement with Kepler Cheuvreux as of December 31, 2023
ORION CORPORATION PRESS RELEASE 8 JANUARY 2024 at 09.00 EET
Here is the original post:
Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs
NeuMoDx CT/NG Assay designed to improve accessibility, affordability and timeliness in sexually transmitted infection (STI) testing in the U.S. // U.S. regulatory clearance of new assay for use on both NeuMoDx 96 and 288 versions of integrated PCR-based clinical molecular testing system // Global presence anchored by 16 EU-certified in-vitro diagnostics (CE-IVD) tests, positioning NeuMoDx as having one of the broadest test menus available to customers NeuMoDx CT/NG Assay designed to improve accessibility, affordability and timeliness in sexually transmitted infection (STI) testing in the U.S. // U.S. regulatory clearance of new assay for use on both NeuMoDx 96 and 288 versions of integrated PCR-based clinical molecular testing system // Global presence anchored by 16 EU-certified in-vitro diagnostics (CE-IVD) tests, positioning NeuMoDx as having one of the broadest test menus available to customers